Feedback / Questions
loxicodegol (NKTR-181) - Nektar Therapeutics
Nektar Therapeutics: Investor and Analyst R&D Day
(Nektar Therapeutics)
-
Oct 11, 2015 -
“NKTR-181 Achieves Maximum Pupil Diameter Reduction Comparable to Oxycodone”
P1 data
•
Pain
http://www.nektar.com/pdf/2015_Nektar_R&D_Day.pdf
Oct 11, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.